DE69329379T2 - Regulation der aktivität von lymphozyten durch hla-peptide - Google Patents
Regulation der aktivität von lymphozyten durch hla-peptideInfo
- Publication number
- DE69329379T2 DE69329379T2 DE69329379T DE69329379T DE69329379T2 DE 69329379 T2 DE69329379 T2 DE 69329379T2 DE 69329379 T DE69329379 T DE 69329379T DE 69329379 T DE69329379 T DE 69329379T DE 69329379 T2 DE69329379 T2 DE 69329379T2
- Authority
- DE
- Germany
- Prior art keywords
- peptides
- hla
- regulation
- domains
- lymphocyte activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56977—HLA or MHC typing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/844,716 US5888512A (en) | 1987-01-30 | 1992-03-02 | Lymphocyte activity regulation by HLA peptides |
PCT/US1993/001758 WO1993017699A1 (en) | 1992-03-02 | 1993-02-25 | Lymphocyte activity regulation by hla peptides |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69329379D1 DE69329379D1 (de) | 2000-10-12 |
DE69329379T2 true DE69329379T2 (de) | 2001-03-29 |
Family
ID=25293452
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69329379T Expired - Fee Related DE69329379T2 (de) | 1992-03-02 | 1993-02-25 | Regulation der aktivität von lymphozyten durch hla-peptide |
Country Status (12)
Country | Link |
---|---|
US (1) | US5888512A (de) |
EP (1) | EP0631502B1 (de) |
JP (1) | JP2846470B2 (de) |
AT (1) | ATE196150T1 (de) |
AU (1) | AU678381B2 (de) |
CA (1) | CA2131299A1 (de) |
DE (1) | DE69329379T2 (de) |
DK (1) | DK0631502T3 (de) |
ES (1) | ES2150949T3 (de) |
GR (1) | GR3034964T3 (de) |
PT (1) | PT631502E (de) |
WO (1) | WO1993017699A1 (de) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5723128A (en) * | 1987-01-30 | 1998-03-03 | The Board Of Trustees Of The Leland Stanford Junior University | Cytotoxic T-cell lymphocyte ("CTL") activity regulation by class I MHC peptides |
US7011834B1 (en) | 1987-01-30 | 2006-03-14 | The Board Of Trustees Of Leland Stanford Junior University | Immunomodulating dimers |
US5639458A (en) * | 1987-03-20 | 1997-06-17 | Regents Of The University Of California | Class I MHC modulation of surface receptor activity |
US5843156A (en) * | 1988-08-24 | 1998-12-01 | Endoluminal Therapeutics, Inc. | Local polymeric gel cellular therapy |
WO1995013288A1 (en) * | 1993-11-10 | 1995-05-18 | The Board Of Trustees For The Leland Stanford Junior University | Surface membrane proteins and their effect on immune response |
US5977300A (en) * | 1994-06-03 | 1999-11-02 | Ludwig Institute Of Cancer Research | Isolated nonapeptide which bind to HLA-B44 molecules and the uses thereof |
EP0804469B1 (de) * | 1995-01-16 | 2001-11-28 | Northern Sydney Area Health Service | T-Zellen beeinflussende Peptide |
US6162434A (en) | 1995-05-03 | 2000-12-19 | Sangstat Medical Corporation | Cytomodulating peptide for inhibiting lymphocyte activity |
US5753625A (en) * | 1995-05-12 | 1998-05-19 | Sangstat Medical Corporation | Treatment for inhibiting the progression of autoimmune disease |
AU1823697A (en) * | 1996-01-02 | 1997-07-28 | Board Of Trustees Of The Leland Stanford Junior University | Interaction of hla proteins with members of the hsp70 family of proteins |
US6436903B1 (en) | 1996-05-22 | 2002-08-20 | Stanford University (Board Of Trustees Of The Leland Standford Junior University) | Immunomodulating compounds comprising d-isomers of amino acids |
ES2193401T3 (es) * | 1996-09-18 | 2003-11-01 | Gerhild Wildner | Peptidos aptos como agente de diagnostico y agente terapeutico para las enfermedades autoinmunitarias. |
WO1998022141A2 (en) * | 1996-11-19 | 1998-05-28 | Sangstat Medical Corporation | Enhanced effects for hapten conjugated therapeutics |
US6696545B1 (en) | 1997-04-11 | 2004-02-24 | Sangstat Medical Corporation | Cytomodulating lipophilic peptides for modulating immune system activity and inhibiting inflammation |
TR199902786T2 (xx) | 1997-04-11 | 2000-06-21 | Sangstat Medical Corporation | Ba����kl�k sistemi faaliyetinin d�zene sokulmas� ve iltihaplanman�n durdurulmas� i�in lipofilik peptidlerin h�cre yap�s�n�n d�zene konulmas�. |
NZ521898A (en) | 2000-03-31 | 2004-11-26 | Purdue Research Foundation | Use of a ligand-immunogen conjugate such as folate-FITC for enhancing an endogenous immune response |
CA2474056A1 (en) | 2002-01-24 | 2003-07-31 | Sangstat Medical Corporation | Combination therapy for treatment of hiv infection |
CA2571710A1 (en) | 2004-06-24 | 2006-11-02 | Nicholas Valiante | Small molecule immunopotentiators and assays for their detection |
EP1982992B1 (de) * | 2006-02-07 | 2010-10-27 | NEC Corporation | Hla bindendes peptid, dessen vorstufe, dafür codierendes dna-fragment und rekombinanter vektor |
TW200745163A (en) * | 2006-02-17 | 2007-12-16 | Syntonix Pharmaceuticals Inc | Peptides that block the binding of IgG to FcRn |
GB0609121D0 (en) * | 2006-05-09 | 2006-06-21 | Univ Birmingham | Peptide Therapy |
WO2008044567A1 (fr) | 2006-10-12 | 2008-04-17 | Nec Corporation | Peptide liant les molécules hla, son précurseur, fragment d'adn le codant et vecteur recombinant |
WO2008139163A1 (en) * | 2007-05-09 | 2008-11-20 | Circassia Limited | Prognostic assay for determining t cell response to hla antigens and use thereof in field of tissue transplantation |
EA201070231A1 (ru) * | 2007-08-09 | 2010-10-29 | Синтоникс Фармасьютикалз, Инк. | Иммуномодулирующие пептиды |
US20100048488A1 (en) * | 2008-08-01 | 2010-02-25 | Syntonix Pharmaceuticals, Inc. | Immunomodulatory peptides |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL69686A (en) * | 1983-09-11 | 1988-03-31 | Yeda Res & Dev | Compositions containing cell membrane proteins and process for their preparation |
US5202424A (en) * | 1984-03-19 | 1993-04-13 | The Rockefeller University | Mesangial cell-derived receptors for advanced glycosylation endproducts and uses thereof |
US4681760A (en) * | 1985-04-17 | 1987-07-21 | The Board Of Trustees Of The Leland Stanford Junior University | Method of conferring immunotolerance to a specific antigen |
AU619458B2 (en) * | 1987-01-30 | 1992-01-30 | Board Of Trustees Of The Leland Stanford Junior University | Lymphocyte inhibition by hla peptides |
AU4030989A (en) * | 1988-02-12 | 1989-09-06 | Regents Of The University Of California, The | Use of synthetic peptides to generate and manipulate cellular immunity |
WO1990010016A1 (en) * | 1989-03-03 | 1990-09-07 | The Regents Of The University Of California | Class i mhc modulation of surface receptor activity |
US5073540A (en) * | 1989-05-15 | 1991-12-17 | Receptron | Composite binding site drugs |
EP0540997A1 (de) * | 1991-11-05 | 1993-05-12 | F. Hoffmann-La Roche Ag | Verfahren und Reagenzien zur Typisierung von HLA-Klass-I-DNS |
-
1992
- 1992-03-02 US US07/844,716 patent/US5888512A/en not_active Expired - Fee Related
-
1993
- 1993-02-25 DE DE69329379T patent/DE69329379T2/de not_active Expired - Fee Related
- 1993-02-25 EP EP93918763A patent/EP0631502B1/de not_active Expired - Lifetime
- 1993-02-25 AU AU48078/93A patent/AU678381B2/en not_active Ceased
- 1993-02-25 AT AT93918763T patent/ATE196150T1/de not_active IP Right Cessation
- 1993-02-25 WO PCT/US1993/001758 patent/WO1993017699A1/en active IP Right Grant
- 1993-02-25 JP JP5515785A patent/JP2846470B2/ja not_active Expired - Fee Related
- 1993-02-25 ES ES93918763T patent/ES2150949T3/es not_active Expired - Lifetime
- 1993-02-25 DK DK93918763T patent/DK0631502T3/da active
- 1993-02-25 PT PT93918763T patent/PT631502E/pt unknown
- 1993-02-25 CA CA002131299A patent/CA2131299A1/en not_active Abandoned
-
2000
- 2000-11-30 GR GR20000402667T patent/GR3034964T3/el not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EP0631502B1 (de) | 2000-09-06 |
AU678381B2 (en) | 1997-05-29 |
DE69329379D1 (de) | 2000-10-12 |
DK0631502T3 (da) | 2001-01-02 |
PT631502E (pt) | 2001-03-30 |
ES2150949T3 (es) | 2000-12-16 |
EP0631502A4 (de) | 1996-07-24 |
US5888512A (en) | 1999-03-30 |
GR3034964T3 (en) | 2001-02-28 |
WO1993017699A1 (en) | 1993-09-16 |
JPH08504168A (ja) | 1996-05-07 |
ATE196150T1 (de) | 2000-09-15 |
JP2846470B2 (ja) | 1999-01-13 |
AU4807893A (en) | 1993-10-05 |
CA2131299A1 (en) | 1993-09-16 |
EP0631502A1 (de) | 1995-01-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69329379T2 (de) | Regulation der aktivität von lymphozyten durch hla-peptide | |
DK0643726T3 (da) | Peptider af humant p53-protein til anvendelse i sammensætninger, som inducerer humant T-celle-respons, og humane p53-protei | |
EP0753005A4 (de) | Die regulation der aktivität zytotoxischer t-zelllymphozyten mit peptiden der mhc-klasse i | |
DE69030212T2 (de) | Verwendung von Derivaten des 4-Phenyl-1,2,3,4-tetrahydro-1-naphthalenamins zur Behandlung von Psychose, Entzündung und als Immununterdrücker | |
DE69329344D1 (de) | Spezifische modulationen des immunsystems | |
DE3854300T2 (de) | Lymphocyteninhibierung durch hla-peptide. | |
DE3889536D1 (de) | Behandlung von krebs mit somatostatin und mit analogen davon. | |
NO985975L (no) | Blandinger og fremgangsmÕter for frembringelse av farmakologisk aktive preparater og anvendelser derav | |
DE69027865D1 (de) | ZUSAMMENSETZUNGEN enthaltend omega Conotoxin Peptide Derivate und deren Verwendung ZUR BEHANDLUNG VON ISCHÄMIE-ARTIGEN NEURONALEN SCHÄDIGUNGEN | |
DK0584136T3 (da) | Bestemmelse af peptidmotiver på MHC-molekyler | |
DK289285A (da) | Thymopentin analoge | |
DK0633763T3 (da) | Kosmetiske eller farmaceutiske sammensætninger indeholdende deacylerede glycerophospholipider til topisk brug | |
NO952385D0 (no) | Fremgangsmåte til identifisering av individer med unormale celler som uttrykker HLA-A2/tyrosinasepeptidantigen | |
DE59209309D1 (de) | Rekombinante antikörper an der oberfläche von e.coli | |
NO970803L (no) | Fremgangsmåte for identifisering av forbindelser egnet for behandling av autoimmune sykdommer | |
ITRM920506A1 (it) | Regioni antigeniche dei complessi tpl e anticorpi diretti contro di essi. | |
ATE317021T1 (de) | Antisense modulierung von lfa-3 | |
FI960839A0 (fi) | Uusia tripeptidejä, jotka ovat käyttökelpoisia immuuni- ja CNS-terapiassa | |
ATE102038T1 (de) | Eliminierung von aktivierten lymphozyten. | |
DK0597043T3 (da) | Porcine adipocytantigener og deres anvendelse til immunologisk bekæmpelse af fedt | |
PT741746E (pt) | Compostos sinteticos relacionados com a timosina alfa1 e novos metodos para a sua sintese | |
IT8320622V0 (it) | Dispositivo di serraggio perestremita' libere di cavi, funi e simili. | |
SU1331063A1 (ru) | ШТАММ TRICHODERMA HARZIANUM RIFAI - ПРОДУЦЕНТ L-ФЕНИЛАЛАНИН-α-ОКСИДАЗЫ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |